ERBB3 and non-small cell lung carcinoma: Among the anti-HER3 monoclonal Abs actively under preclinical investigations and clinical testing [21, 37–39], two of them - MM-121 (or seribantumab, Merrimack Pharmaceuticals, Inc.)and patritumab (Daiichi-Sankyo Co. Ltd., Tokyo, Japan) - have shown encouraging clinic benefits in patients with non-small cell lung cancer [40, 41].